An initial study published in The Journal of Urology®, an International Journal of the American Urological Association (AUA), says that a novel surgical robotic system is “feasible, safe, and successful” for treating early-stage prostate cancer.
A new surgical robotic system is "feasible, safe, and effective" for treatment of early-stage prostate cancer, concludes an initial evaluation in The Journal of
Trial PROSPERs China’s fight against advancing prostate cancer
New results from the PROSPER trial helped persuade the Chinese government to approve enzalutamide for adult patients diagnosed with advanced non-metastatic castration-resistant prostate cancer,
Peter Doyle reports
It might be coincidental. But eight months after a joint study by the Peking First University Hospital and National Urological Cancer Center of China in Beijing found a lack of effective therapies in the world’s most populous country for patients with advanced prostate cancer, China’s medicine regulator, the National Medical Products Administration (NMPA), approved the oral androgen-receptor inhibitor enzalutamide for the treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) with high risk of metastasis.